Oyster Point Pharma Inc

Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma’s lead product candidate, OC-01, a highly selective nicotinic acetylcholine receptor (nAChR) agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. Dry eye disease is a chronic, progressive condition that impacts more than 30 million Americans and is growing in prevalence. OC-01’s novel mechanism of action re-establishes tear film homeostasis by activating the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the Lacrimal Functional Unit (LFU).

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharmaâ??s lead product candidate, OC-01, a highly selective nicotinic acetylcholine receptor (nAChR) agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. Dry eye disease is a chronic, progressive condition that impacts more than 30 million Americans and is growing in prevalence. OC-01â??s novel mechanism of action re-establishes tear film homeostasis by activating the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the Lacrimal Functional Unit (LFU).

Viatris

NEW ORLEANS--( BUSINESS WIRE )--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Oyster Point Pharma, Inc. (NasdaqGS: OYST) to Viatris Inc. (NasdaqGS: VTRS). Under the terms of the proposed transaction, shareholders of Oyster Point will receive $11.00 in cash plus a contingent value right for a potential cash payment of up to $2.00 per share, for each share of Oyster Point that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

OYSTER POINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Oyster Point Pharma, Inc. - OYST

PRINCETON, N.J., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that the Compensation Committee of the Company's Board of Directors granted inducement non-qualified stock options to purchase an aggregate of 11,300 shares of common stock to three new employees, pursuant to the Oyster Point Pharma, Inc., 2021 Inducement Incentive Plan.

Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wilmington, Delaware--(Newsfile Corp. - November 21, 2022) - Rigrodsky Law, P.A. is investigating Oyster Point Pharma, Inc. ("Oyster") (NASDAQ: OYST) regarding possible breaches of fiduciary duties and other violations of law related to Oyster's agreement to be acquired by Viatris Inc. Under the terms of the agreement, Oyster's shareholders will receive $11.00 per share and a contingent value right for a potential cash payment of up to $2.00 per share.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Oyster Point Pharma, Inc. Buyout

NEW YORK , Nov. 14, 2022 /PRNewswire/-- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Oyster Point Pharma, Inc. (OYST), relating to its proposed acquisition by Viatris Inc. Under the terms of the agreement, OYST shareholders will receive $11.00 in cash plus up to $2.00 per share in CVRs per share they own. Click here for more information: https://www.monteverdelaw.com/case/oyster-point-pharma-inc.

INVESTOR ALERT: The M&A Class Action Firm Announces the Investigation of Oyster Point Pharma, Inc. - OYST

OYSTER PT PHARM (OYST) delivered earnings and revenue surprises of 9.87% and 24.50%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

OYSTER PT PHARM (OYST) Reports Q3 Loss, Lags Revenue Estimates

PRINCETON, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced its financial results for the quarter ended September 30, 2022, and provided an overview of recent business highlights.

Oyster Point Pharma Reports Third Quarter 2022 Financial Results and Recent Business Highlights

NEW YORK , Nov. 7, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Oyster Point Pharma, Inc. ("Oyster Point" or the "Company") (NASDAQ: OYST), in connection with the proposed acquisition of the Company by Viatris Inc. (NASDAQ: VTRS) via tender offer. Under the terms of the merger agreement, the Company's shareholders will receive $11.00 in cash for each share of Oyster Point common stock owned, plus a contingent value right ("CVR") representing the right to receive a potential cash payment of up to $2.00 per share.

SHAREHOLDER ALERT: Weiss Law Investigates Oyster Point Pharma, Inc.

Viatris (VTRS) announced it is buying Oyster Point Pharma (OYST). This is why.

Why Viatris (VTRS) Is Buying Oyster Point (OYST)

MILWAUKEE , Nov. 7, 2022 /PRNewswire/ -- Ademi LLP is investigating Oyster Point Pharma (NASDAQ: OYST) for possible breaches of fiduciary duty and other violations of law in its transaction with Viatris.  Click here to learn how to join the action https://www.ademilaw.com/case/oyster-point-pharma-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Oyster Point Pharma, Inc. has obtained a Fair Price in its transaction with Viatris

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Oyster Point Pharma, Inc. (NASDAQ: OYST) to Viatris Inc. for $11.00 per share in cash plus a contingent value right for a potential cash payment of up to $2.00 per share is fair to Oyster Point shareholders.

OYST Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Oyster Point Pharma, Inc. Is Fair to Shareholders

PRINCETON, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”), today announced that it has entered into a definitive agreement under which Viatris Inc. (Nasdaq: VTRS), a global healthcare company, would acquire Oyster Point Pharma, a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases. Viatris intends to acquire Oyster Point Pharma as the foundation of its new ophthalmology franchise, recognizing its uniquely talented team, the strength of TYRVAYA ® (varenicline solution) Nasal Spray and Oyster Point Pharma's pipeline.

Oyster Point Pharma, a Leading Ophthalmology-Focused Biopharmaceutical Company, to be Acquired by Viatris

Conference Call and Webcast Scheduled for November 10, 2022, 4:30 p.m. ET Conference Call and Webcast Scheduled for November 10, 2022, 4:30 p.m. ET

Oyster Point Pharma To Report Third Quarter 2022 Financial Results On November 10, 2022

Two Featured Presentations will Include a Post-Hoc Analysis of TYRVAYA® (varenicline solution) Nasal Spray and Tear Film Cytokine Research Two Featured Presentations will Include a Post-Hoc Analysis of TYRVAYA® (varenicline solution) Nasal Spray and Tear Film Cytokine Research

Oyster Point Pharma to Present New Scientific Analyses at World Cornea Congress VIII

PRINCETON, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that the Compensation Committee of the Company's Board of Directors granted inducement non-qualified stock options to purchase an aggregate of 242,600 shares of common stock to 36 new employees, pursuant to the Oyster Point Pharma, Inc., 2021 Inducement Incentive Plan.

Oyster Point Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRINCETON, N.J., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced the presentation of analyses at the Women in Ophthalmology (WIO) Summer Symposium, which is taking place in Monterey, California from August 25-28, 2022.

Oyster Point Pharma to Present Analyses at the Women in Ophthalmology Summer Symposium

PRINCETON, N.J., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that the largest Medicare Pharmacy Benefit Manager in the United States will add TYRVAYA® Nasal Spray on its Medicare Part D formularies, effective September 1, 2022.

Oyster Point Pharma Announces TYRVAYA® To Be Covered By the Largest Medicare Pharmacy Benefit Manager

Oyster Point Pharma, Inc. (NASDAQ:OYST ) Q2 2022 Results Conference Call August 11, 2022 4:30 PM ET Company Participants Arty Ahmed - Vice President, Investor Relations Dr. Jeffrey Nau - President and Chief Executive Officer Dan Lochner - Chief Financial Officer and Chief Business Officer Michael Campbell - Senior Vice President and Head of Commercial Conference Call Participants Patrick Dolezal - LifeSci Capital Ken Cacciatore - Cowen Joe Catanzaro - Piper Sandler Daniil Gataulin - Chardan Operator Good day, and thank you for standing by. Welcome to the Oyster Point Pharma Second Quarter 2022 Earnings Conference Call.

Oyster Point Pharma, Inc. (OYST) CEO Dr. Jeffrey Nau on Q2 2022 Results - Earnings Call Transcript

OYSTER PT PHARM (OYST) delivered earnings and revenue surprises of -14.02% and 2.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

OYSTER PT PHARM (OYST) Reports Q2 Loss, Lags Revenue Estimates

PRINCETON, N.J., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced its financial results for the quarter ended June 30, 2022, and provided an overview of recent business highlights.

Oyster Point Pharma Reports Second Quarter 2022 Financial Results and Recent Business Highlights

Conference Call and Webcast Scheduled for August 11, 2022, 4:30 p.m. ET

Oyster Point Pharma To Report Second Quarter 2022 Financial Results On August 11, 2022

PRINCETON, N.J., July 27, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced the expansion of patient access to TYRVAYA® (varenicline solution) Nasal Spray and provided an update on the commercial performance of TYRVAYA in the U.S.

Oyster Point Pharma Announces Expanded Patient Access to TYRVAYA®

The consensus price target hints at a 423.5% upside potential for OYSTER PT PHARM (OYST). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Think OYSTER PT PHARM (OYST) Could Surge 423%: Read This Before Placing a Bet

OYST has an approved product that is highly competitive against a blockbuster drug. They seem to have executed commercialization pretty well, except in the bottom line.

Oyster Therapeutics: State Of Business Is Confounding

Plan to Continue to Drive TYRVAYA ® Launch with Approximately 150-200 Field-Based Sales Resources

Oyster Point Pharma Announces Operating Expense Streamlining Plan

Scientific Poster Examines Effects of Treatment in Broad Spectrum of Dry Eye Disease Patients Scientific Poster Examines Effects of Treatment in Broad Spectrum of Dry Eye Disease Patients

News for Oyster Point Pharma Inc Stock (OYST)